CD138和乙酰肝素酶在膀胱癌中的表达和临床意义

Expression and clinical significance of CD138 and heparanase in bladder carcinoma

目的:探讨膀胱癌中CD138和乙酰肝素酶的表达水平及其与膀胱癌发生、发展、复发和转移的关系。方法:应用免疫组化Envision二步法研究58例膀胱中CD138和乙酰肝素酶的表达水平。结果:CD138在膀胱癌中的阳性表达35例(60.3%),其表达率与肿瘤的病理分级、临床分期、复发和淋巴结转移无相关性(P>0.05)。乙酰肝素酶在膀胱癌中阳性表达22例(37.9%),其表达率与肿瘤的病理分级、临床分期、复发和淋巴结转移有相关性(P<0.01)。CD138和乙酰肝素酶表达呈正相关(P<0.01),其共同表达与肿瘤的病理分级、临床分期、复发和淋巴结转移有相关性(P<0.05)。结论:CD138和乙酰肝素酶蛋白的共同表达能成为膀胱癌发生和发展的预后参数。

Objective：To study the expression of CD138 and heparanase in bladder carcinoma and the relation ship with its development, progression, recrudescence and metastasis. Methods： Immunohistochemical technique was used to detect the expression of CD138 and heparanase in 58 cases of bladder carcinoma. Results：The positive protein expression of CD138 was 60.3% （35/58）, The CD138 protein expression was not correlated with the pathological type, clinical stage, recrudescence and lymph node metastasis （P〉0.05）, The positive protein ex pression of heparanase was 37.9% （22/58）. The heperanase protein expression was correlated with the pathological type, clinical stage, recrudescence and lymph node metastasis （P〈0.05）, The positive protein co expression of CD138 and heperanase was correlated with the pathological type, clinical stage, recrudescence and lymph node metastasis （P〈0.05）. Conclusions：Co-expression of CD138 and heparanase protein might serve as marker for the prognosis bladder carcinoma.